Responses and communications regarding WHO Expert Committee on Drug Dependence questionnaires

Gregory Foster filed this request with the Department of Health and Human Services of the United States of America.

It is a clone of this request.

Tracking #

2017-10148

Due Nov. 20, 2017
Est. Completion None
Status
Awaiting Response

Communications

From: Gregory Foster

To Whom It May Concern:

This is a request under the federal Freedom of Information Act, 5 U.S.C. § 552. I hereby request the following records:

I request access to and copies of the FDA's response to the World Health Organization (WHO) request for member state feedback on substances under evaluation during the 39th meeting of the WHO Expert Committee on Drug Dependence (ECDD); and access to and copies of all records of communications concerning the WHO request for feedback along with associated metadata.

According to docket FDA-2017-N-4515 filed by HHS in the Federal Register, the WHO asked member states to provide input on "...legitimate use, harmful use, status of national control and potential impact of international control for each substance under evaluation" through an online portal. Replies from members states had to reach the WHO Secretariat by September 30, 2017.
https://www.regulations.gov/docket?D=FDA-2017-N-4515

If it can prove helpful as a starting point, the FDA docket indicates that HHS's primary point of contact for this initiative is:
James R. Hunter
Center for Drug Evaluation and Research, Controlled Substance Staff, Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 5150
Silver Spring, MD 20993-0002
301-796-3156
email: james.hunter@fda.hhs.gov

I would prefer the request be filled electronically via e-mail attachment if available, or DVD-ROM/CD-ROM if not.

I request a waiver of any applicable fees. Release of the information is in the public interest because it will contribute significantly to public understanding of government operations and activities. The requested records will be made available to the general public free of charge as part of the public information service at MuckRock.com, processed by a representative of the news media/press. This request is made in the process of news gathering and is not for commercial usage.

In the event that there are fees, I would be grateful if you would inform me of the total charges in advance of fulfilling my request.

If my request is denied in whole or part, I ask that you justify all deletions by reference to specific exemptions of the act. I request that any deletions be "blacked out" rather than "whited out". Please release all segregable portions of otherwise exempt material. I am aware of my rights to appeal a decision to withhold information or deny a waiver of fees.

Thank you in advance for your cooperation in this matter. I look forward to receiving your response to this request within 20 business days, as the statute requires.

Sincerely,

Gregory Foster

From:

RE: 2018-00060-FOIA-OS Gregory Foster
MuckRock
DEPT MR 411A Highland Avenue
Somerville, MA 02144-2516 Dear Foster: This is in response to your Freedom of Information Act (FOIA) request, dated: October 05, 2017 , concerningyour request on . We received “Requesting copies of the FDA's response to the World Health Organization (WHO) request for member state feedback on substances under evaluation during the 39th meeting of the WHO Expert Committee on Drug Dependence (ECDD); and access to and copies of all records of communications concerning the WHO request for feedback along with associated metadata.According to docket FDA-2017-N-4515 filed by HHS in the Federal Register, the WHO asked member states to provide input on "...legitimate use, harmful use, status of national control and potential impact of international control for each substance under evaluation" through an online portal. Replies from members states had to reach the WHO Secretariat by September 30, 2017.https://www.regulations.gov/docket?D=FDA-2017-N-4515” October 11, 2017 and are referring it to the Food and Drug Administration (FDA) for direct response to you. You may check on the status of your request with FDA at (301) 796-3900. Sincerely,
Michael Bell
Deputy Director Main Office Line:  202-690-7453

From:

An interim response, stating the request is being processed.

Files

pages

Close